Neurology 57:15151517 Coles LD, Tuite PJ, Oz G, Mishra UR, Kartha RV, Sullivan KM, Cloyd JC, Terpstra M (2018) Repeated-dose oral N-acetylcysteine in Parkinson's disease: pharmacokinetics and effect on brain glutathione and oxidative stress
The guidelines are as follows: 503A: Must comply with State Board of Pharmacy
10.1038/s41564-018-0307-3 415 SudoN.ChidaY.AibaY.SonodaJ.OyamaN.YuX.-N.et al
It has been assessed in clinical trials by Merrion Pharma as an oral solid-dosage form (GIPET TM ) for enhancing the absorption of Biopharmaceutical Class System III small molecules such as zoledronic acid and alendronate and macromolecules including insulin, desmopressin, and antisense oligonucleotides (Leonard et al., 2006)
supports For the latest stories on the science of healthy living, subscribe to NPR's Health newsletter